---
title: "Combined-modality therapies-of-renal-cell-carcinoma"
date: "2024-01-03 11:11:04"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ±ä¾†è‡ª: [[renal-cell-carcinoma]]

# Combined-modality therapies-of-renal-cell-carcinoma

\*\*1Â° endpoint(s) listed below include PFS &/or median OS

Axitinib+avelumab (NEJM 2019; 380:1103) vs. sunitinib: PFS: 13.8 mos vs. 8.4 mos (HR: 0.69, P <0.001); OS for PD-L1-high 86.3% vs. 84.8% (HR for death: 0.82, P = 0.38)
Axitinib+pembrolizumab (NEJM 2019;380:1116) vs. sunitinib: PFS: 15.1 mos vs. 11.1 mos (HR: 0.69, P <0.001); OS 89.9% vs. 78.3% (HR for death 0.53, P <0.0001)
Cabozantinib+nivolumab (NEJM 2021;384:829) vs. sunitinib: PFS 16.6 mos vs. 8.3 mos (HR: 0.51, P <0.001)
Lenvatinib+everolimus (NEJM 2021;384:1289) vs. sunitinib: PFS: 14.7 mos vs. 9.2 mos (HR: 0.65, P <0.001)
Lenvatinib+pembrolizumab (NEJM 2021;384:1289) vs. sunitinib: PFS 23.9 mos vs. 9.2 mos (HR: 0.39, P <0.001)

### Siblings

- [[Epidemiology-of-renal-cell-carcinoma]]
- [[Histology and molecular biology-of-renal-cell-carcinoma]]
- [[Hereditary RCC and germline testing-of-renal-cell-carcinoma]]
- [[Clinical presentation-of-renal-cell-carcinoma]]
- [[Staging (TNM classification) and prognosis-of-renal-cell-carcinoma]]
- [[Treatment principles-of-renal-cell-carcinoma]]
- [[Systemic therapy for metastatic clear cell RCC]]
- [[Second-line therapies-of-renal-cell-carcinoma]]
- [[Combined-modality therapies-of-renal-cell-carcinoma]]
- [[Tyrosine kinase inhibitors-of-renal-cell-carcinoma]]
- [[Immunotherapies-of-renal-cell-carcinoma]]
- [[mTOR inhibitors-of-renal-cell-carcinoma]]
- [[Non-clear cell histology-of-renal-cell-carcinoma]]

